tbuckley/cabot-search huggingface dataset:
Abstract 15656: Manual vs Remote Magnetic Navigation for Ventricular Tachycardia Ablation: A Meta-analysis
Authors: Ghulam Murtaza, Mohit K Turagam, Jalaj Garg, Krishna Akella, Donita Atkins, Scott M Koerber, Rakesh Gopinathannair, Dhanunjaya Lakkireddy
Journal: Circulation (2020)

Introduction: The role of remote magnetic navigation (RMN) for ventricular tachycardia (VT) ablation is not well established. In this meta- analysis, we aim to evaluate the safety and efficacy of RMN vs manual navigation (MAN) for VT ablation. Methods: A comprehensive literature search in PubMed, Google Scholar and Cochrane Review from inception till November 9th, 2019 was performed. Studies reporting clinical outcomes comparing MAN vs RMN were included. Two investigators independently extracted the data and individual quality assessment was performed. Results were expressed as odds ratio (OR) for dichotomous outcomes and mean differences (MD) for continuous variables with 95% confidence intervals (CI). Results: Eight studies including a total of 861 patients (475 in RMN arm and 386 in MAN arm) were included in the final analysis. VT recurrence was significantly lower with RMN compared with MAN (OR 0.65, 95% CI 0.48-0.88, p= 0.005). Acute procedural success was significantly higher with RMN (OR 2.21, 95% CI 1.51-3.23, p &lt; 0.0001). Total procedure time [MD -8.83, 95% CI -17.72- 0.05, p=0.05], fluoroscopy time [MD -10.24, 95% CI -12.28- -8.19, p= 0.00001), and complications [OR 0.36, 95% CI 0.18- 0.72, p= 0.003] were significantly lower in RMN compared to MAN. Conclusion: Results of our meta-analysis indicate that RMN is safer and more effective than MAN in patients with VT undergoing ablation. Further, randomized studies are needed to validate these findings.
Abstract P102: Variability In Lipid Levels And Risk For Cardiovascular Disease: An Electronic Health Record-based Population Cohort Study
Authors: Sheila M Manemann, Suzette J Bielinski, Ethan D Moser, Jennifer L St. Sauver, Paul Y Takahashi, Veronique L Roger, Janet E Olson, Paul A Decker, Jill M Killian, Nicholas B Larson
Journal: Circulation (2021)

Background: Larger within-patient variability of lipid levels has been associated with an increased risk of cardiovascular disease (CVD). However, measures of lipid variability are not currently used clinically. We investigated the feasibility of calculating lipid variability within a large electronic health record (EHR)-based population cohort and assessed associations with incident CVD. Methods: We identified all individuals ≥40 years of age who resided in Olmsted County, MN on 1/1/2006 (index date) without prior CVD. CVD was defined as myocardial infarction, coronary artery bypass graft surgery, percutaneous coronary intervention or stroke. Patients with ≥3 measurements of total cholesterol, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and/or triglycerides during the 5 years before the index date were retained in the analyses. Lipid variability was calculated using variability independent of the mean (VIM). Patients were followed through 9/30/2017 for incident CVD (including CVD death). Cox regression was used to investigate the association between quintiles of lipid VIMs and incident CVD. Results: We identified 18,642 individuals (mean age 60; 55% female) who were free of CVD at baseline and VIM calculated for at least one lipid measurement. After adjustment, those in the highest VIM quintiles of total cholesterol had a 25% increased risk of CVD (Q5 vs. Q1 HR: 1.25, 95% CI: 1.08-1.45; Table). We observed similar results for LDL-C (Q5 vs. Q1 HR: 1.20, 95% CI: 1.04-1.39) and HDL-C (Q5 vs. Q1 HR: 1.25, 95% CI: 1.09-1.43). There was no association between triglyceride variability quintiles and CVD risk. Conclusion: In a large EHR-based population cohort, high variability in total cholesterol, HDL-C and LDL-C was associated with an increased risk of CVD, independently of traditional risk factors, suggesting it may be a target for intervention. Lipid variability can be calculated in the EHR environment but more research is needed to determine its clinical utility.
Abstract 15981: Cost-effectiveness of Dapagliflozin in Heart Failure With Reduced Ejection Fraction
Authors: Nicolas Isaza, Paola Calvachi, Inbar Raber, Changyu Shen, Michael C Gavin, A. Reshad Garan, Brandon K Bellows, Dhruv S Kazi
Journal: Circulation (2020)

Introduction: In May 2020, the US FDA approved the use of dapagliflozin, an SGLT2 inhibitor, for the reduction of cardiovascular death and heart failure hospitalization in patients with heart failure with reduced ejection fraction (HFrEF). We examined the cost-effectiveness of adding dapagliflozin to guideline-directed medical therapy (GDMT) in patients with or without diabetes. Methods: We developed a state-transition Markov model with inputs from the DAPA-HF trial, FDA review documents, published literature, and nationally representative datasets (Panel A). The model was calibrated to event rates observed in DAPA-HF; survival was extrapolated using non-parametric approaches. The main outcomes were quality-adjusted life years (QALYs) and incremental cost effectiveness ratio (ICER) of dapagliflozin + GDMT compared with GDMT alone, from a healthcare sector perspective and a lifetime analytic horizon. We applied a discount rate of 3% per year for future costs and benefits, and assumed a willingness-to-pay threshold of $100,000 per QALY gained. In sensitivity analyses, we examined subgroups with or without diabetes, and varied the cost of dapagliflozin (base case = $6,188 per year). This analysis was independent of the trial sponsor. Results: Compared with GDMT alone, adding dapagliflozin produced 0.57 additional QALYs at an incremental cost of $56,650, producing an ICER of $98,700 per QALY gained (Panel B). In subgroup analyses, dapagliflozin produced 0.71 additional QALYs in patients with diabetes at an ICER of $89,100 per QALY gained, and 0.48 additional QALYs in patients without diabetes at an ICER of $108,800 per QALY (Panels C and D). A 9% price reduction (to $5,613 per year) would make dapagliflozin cost-effective in patients without diabetes. Conclusions: Adding dapagliflozin to GDMT in patients with HFrEF is cost-effective and has the potential to improve long-term outcomes. Scalable strategies to improve access and uptake are urgently required.
In Vivo HSC Gene Therapy with High-Level, Erythroid-Specific Expression of a Secreted SARS-CoV-2 Decoy Receptor
Authors: H. J. Wang, S. Gil, C. Li, C. Doering, P. Ng, S. Roffler, H. P. Kiem, A. L. Lieber
Journal: Molecular Therapy (2021)
Abstract 11814: Is Cardiovascular Risk and Mortality in Rheumatoid Arthritis Compared to Diabetes Mellitus and the General Population Overestimated?
Authors: Brian B Logstrup, Torkell Ellingsen, Alma B Pedersen, Bianka B Darvalics, Kevin K Olesen, Hans Erik Bøtker, Michael Mæng
Journal: Circulation (2019)

Introduction: Patients with rheumatoid arthritis (RA) have an increased cardiovascular risk compared to non-RA patients, however the magnitude is unexplored for all entities of cardiovascular disea...
65P Patient follow-up of NEOVATTL study
Authors: B. Vieites, M.Á. López-García, M.D. Martín-Salvago, C.L. Ramírez-Tortosa, R. Rezola, M. Sancho de Salas, L. López Vilaró, F. Vilardell Villellas, O. Burgués, B. Fernández-Rodríguez, L. Alfaro Galán, V. Peg
Journal: Annals of Oncology (2021)
Abstract 053: Association Of Pre-pregnancy Cardiovascular Health With Adverse Maternal And Fetal Outcomes
Authors: Michael C Wang, Priya M Freaney, Amanda M Perak, Norrina B Allen, Philip Greenland, William A Grobman, Donald M Lloyd-Jones, Sadiya S Khan
Journal: Circulation (2021)

Introduction: Individual pre-pregnancy risk factors such as obesity, hypertension, and diabetes disproportionately affect minority women and are associated with adverse maternal and offspring outcomes. However, quantification of pre-pregnancy cardiovascular health (CVH) and association with pregnancy outcomes is lacking and can help identify at-risk women and children. Hypothesis: Suboptimal pre-pregnancy CVH is associated with higher risk of adverse maternal and fetal outcomes. Methods: We conducted a cross-sectional study using the CDC Natality files, which include all pregnancies in the US that resulted in live birth or fetal death after 20 weeks. Our study sample consisted of data from singleton live births or fetal deaths to women aged 15-44 years in 2018. Four maternal metrics (body mass index, smoking, diabetes, and hypertension) were assigned 1 point each for pre-pregnancy BMI &lt; 25.0 kg/m 2 , non-smoking, and absence of hypertension or diabetes to construct a pre-pregnancy clinical CVH score ranging from 0-4. We examined the distribution of CVH by race/ethnicity. We then quantified associations of CVH with maternal ICU admission, preterm birth (PTB), low birthweight (LBW), and fetal death using logistic regression (CVH = 4 as the referent) adjusted for maternal age, race/ethnicity, education, prenatal care, and parity. Results: Of 3,582,832 pregnancies in 2018, more than half of women had a suboptimal CVH score (CVH = 3: 51.8%; CVH = 2: 6.7%; CVH = 0/1: 0.4%). Suboptimal CVH score (&lt;4) was more prevalent in non-Hispanic Black (67.8%) and Hispanic (63.1%) than in non-Hispanic White (57.2%) and Asian (36.8%) women ( Figure) . There were consistent and inverse graded associations between CVH score of 3, 2, and 0/1 (compared with 4 as the referent) and maternal ICU admission, PTB, LBW, and fetal death (p&lt;0.001). Conclusions: Pre-pregnancy clinical CVH score has strong, graded associations with adverse maternal and fetal outcomes, with disproportionate impact of suboptimal CVH in non-Hispanic Black and Hispanic women.
41O Nine weeks vs 1-year adjuvant trastuzumab: Long term outcomes of the ShortHER randomised trial
Authors: P.F. Conte, A. Frassoldati, G. Bisagni, A.A. Brandes, M. Donadio, O. Garrone, F. Piacentini, L. Cavanna, F. Giotta, M. Aieta, V. Gebbia, A. Musolino, A. Ferro, S. Danese, C. Zamagni, O. Nanni, M.V. Dieci, R. Vicini, S. Balduzzi, V. Guarneri
Journal: Annals of Oncology (2021)
冠動脈疾患において通常ケア・コレステロール低下薬と比べ、更に冠動脈イベントと心筋灌流異常を減らす複合的で激しい生活様式および薬理学的脂質治療
Authors: Sdringola S, Nakagawa K, Nakagawa Y, Yusuf Sw, Boccalandro F, Mullani N, Haynie M, Hess Mj, Gould Kl
Journal: Journal of the American College of Cardiology (2003)
Abstract 15977: Comparison of Clinical and Procedural Outcomes Between High-power Short-duration, Standard-power Standard-duration, and Temperature-controlled Non-contact Force Guided Ablation for Atrial Fibrillation
Authors: Sean J Dikdan, Joey Junarta, Sairamya Bodempudi, Naman Upadhyay, Zachary Pang, Daniel R Frisch
Journal: Circulation (2020)

Introduction: High-power short-duration (HPSD) ablation via the St. Jude EnSite™ Velocity™ system (St. Paul, MN) utilizes 50W delivered for up to 15s, guided by a Lesion Size Index of 5-6 specific to the Velocity™ system. HPSD is a novel way to use a contact force-sensing catheter optimized for power-controlled radiofrequency ablation of atrial fibrillation (AF). Procedural and clinical outcomes of HPSD compared to standard-power standard-duration (SPSD; 20-25W until 400-500 gram seconds, up to 60s) and temperature-controlled non-contact (TCNC; 20-40W up to 60s of ablation) settings would inform this strategy. Methods: We studied consecutive cases of patients with paroxysmal or persistent AF undergoing pulmonary vein isolation (PVI) with TCNC, SPSD, and HPSD between 7/1/13 to 11/1/19. Procedural data collected include total radiofrequency time (RFT), time to isolate the left pulmonary veins (LPVT), time to isolate the right pulmonary veins (RPVT), and safety outcomes. Clinical data collected include sinus rhythm maintenance 3 and 12-months post-procedure. Results: A total of 171 patients were studied (44 TCNC, 51 SPSD, 76 HPSD). There was no difference in age, sex, or AF type between groups. RFT was shorter when comparing HPSD to SPSD (71 vs 101 min; p&lt;0.01), HPSD to TCNC (71 vs 146 min; p&lt;0.01), and SPSD to TCNC groups (101 vs 146 min; p&lt;0.01). This was driven by decreases in LPVT between the HPSD vs SPSD (34 vs 46 min; p=0.04), HPSD vs TCNC (34 vs 72 min; p&lt;0.01), and SPSD vs TCNC groups (46 vs 72 min; p&lt;0.01), as well as decreases in RPVT between the HPSD vs SPSD (42 vs 54 min; p=0.03), HPSD vs TCNC (42 vs 75 min; p&lt;0.01), and SPSD vs TCNC groups (54 vs 75 min; p&lt;0.01). There was no difference in sinus rhythm maintenance after 3 or 12-months between groups overall, and when stratified by AF type, left atrial volume, CHA 2 DS 2 -VASc score, or left ventricular EF. There was a numerical difference in safety with no adverse events in HPSD (0/76 in HPSD vs 1/51 in SPSD vs 3/44 in TCNC; p=0.06). Conclusion: AF ablation with contact force utilizing an HPSD ablation strategy reduced procedure times with similar sinus rhythm maintenance compared to SPSD and TCNC approaches. Further research is needed to determine whether clinical outcomes differ with a larger population and longer follow-up.
マトリックス・メタロプロテイナーゼの抑制による喘息ネズミ・モデルにおけるアレルゲン誘発性気道炎症の防止
Authors: Kumagai K, Ohno I, Okada S, Ohkawara Y, Suzuki K, Masu K, Shinya T, Nagase H, Iwata K, Shirato K
Journal: American Journal of Respiratory and Critical Care Medicine (1999)
Abstract 12659: Improved Heart Transplant Outcomes Among Patients With Hepatitis C Virus Infection in the Era of Direct-acting Antiviral Agents
Authors: Tomohiro Fujisaki, Takahisa Mikami, Toshiki Kuno, Noah Moss, Shinobu Itagaki
Journal: Circulation (2020)

Introduction: The effect of hepatitis C virus (HCV) infection in recipients or donors on heart transplants is less known in the era after the introduction of direct-acting antiviral agents (DAAs). Methods: Using the United Network for Organ Sharing registry, 25,581 adult heart transplant recipients between 2005 and 2019 were identified. The trend in prevalence of HCV infected recipients and in utilization of HCV infected donors and their effect on the transplant outcomes were investigated in the pre-DAAs era versus the DAAs era separated by May 13, 2011, using Cox proportional hazard regression. Results: HCV antibody positive recipients (n=532, 2.1%) had stable prevalence ( P =0.18) with a higher mortality risk in the pre-DAAs era (50.8% versus 38.8% at 10 years; hazard ratio (HR), 1.50; 95% confidence interval (CI), 1.22-1.85; P &lt;0.001), however not in the DAAs era (25.3% versus 28.4% at 7 years; HR, 0.96; 95% CI, 0.72-1.28; P =0.79) ( P interaction&lt;0.001). Organ use from HCV antibody positive donors (n=375, 1.5%) was exclusively concentrated in the recent years ( P &lt;0.001) and provided the similar mortality up to 2 years (15.7% versus 12.4%; HR, 0.96; 95% CI, 0.65-1.43; P =0.84) regardless of the recipient HCV antibody status. The similar findings were confirmed with a subgroup cohort with positive nucleic acid amplification test (NAT). Conclusions: In the DAAs era, positive HCV antibody in recipients did not adversely affect the long-term transplant outcomes. Graft utilization from positive HCV antibody or NAT positive donors are rapidly more prevalent and appeared to be promising up to 2 years post-transplant.
LBA3 Atezolizumab with carboplatin as immune induction in metastatic lobular breast cancer: First results of the GELATO-trial
Authors: L. Voorwerk, H. Horlings, M. Van Dongen, K. Sikorska, I. Kemper, I. Mandjes, J. Van Geel, J. Boers, M. De Boer, R. Salgado, G. Sonke, K. De Visser, T. Schumacher, C. Blank, A. Jager, C. Schroder, V. Tjan-Heijnen, S. Linn, M. Kok
Journal: Annals of Oncology (2021)
植込み型除細動器(ICD)を使用中の患者の精神状態の追跡試験から継続的な心理的ケアの重要性が示された
Authors: Ihara Yashiko, Chishaki Akiko, Miyazono Mami, Makaya Miyuki, Inoue Shujiro, Mukai Yasushi, Takemoto Masao, Chishaki Hiroaki, Sunagawa Kenji
Journal: Circulation (2011)
Abstract P063: Afro Caribbeans With Type 2 Diabetes Have Lower Body Mass Index And Lower Waist Circumference Than African Americans: New York City Health And Nutrition Examination Survey 2013/14
Authors: Maria Farag, Faustine Williams, Margrethe F Horlyck-Romanovsky
Journal: Circulation (2021)

African descent populations are experiencing a disproportionate burden of type 2 diabetes. In New York City, almost one third of the Black population are foreign-born Afro-Caribbeans and two thirds are African American. We compared type 2 diabetes risk profiles and disease burden among foreign-born Afro-Caribbean and US-born African American New Yorkers by estimating: a) Prevalence of type 2 diabetes; b) Type 2 diabetes risk profile by ethnicity and c) Odds of type 2 diabetes. Using the 2013/14 New York City Health and Nutrition Examination Survey probability sample weighted to the New York City population, we analyzed data for Afro-Caribbean (n=81) and African American (n=118) participants. Type 2 diabetes was defined as prior diagnosis; or HbA1c≥6.5%; or fasting glucose ≥126mg/dL. Logistic regression estimated odds of type 2 diabetes by BMI category, waist circumference (cm), and physical activity; adjusting for age, sex, education, income, and marital status. Among Afro-Caribbeans (Age (Mean ±SE) 49±2years, BMI 29.2 ±0.7kg/m 2 ) and African Americans (Age 46±2years, BMI 30.3 ±0.9kg/m 2 ) type 2 diabetes prevalence was 31% (25 of 81) and 21% (25 of 118) respectively. Compared to African Americans with type 2 diabetes, Afro-Caribbeans with type 2 diabetes had lower mean BMI (29.9 ±0.8kg/m 2 vs. 34.6 ±1.78kg/m 2 , P =0.01), and lower waist circumference (102 ±2cm vs. 114 ±3cm, P =0.0015). Afro-Caribbeans with type 2 diabetes were more likely to be overweight (57.2% vs. 13.5%) rather than obese (33.2% vs. 74.7%), yet less likely to meet HP2010 physical activity goals (23.6% vs 35.3%). Overall type 2 diabetes odds were no different between groups. In the total population odds were 5% higher for each cm waist circumference [aOR=1.05 (95% CI 1.01-1.10), P =0.0194]. Compared to the youngest age group, ages 20-49y, type 2 diabetes odds were higher among ages 50-59y [aOR=7.12 (95% CI 2.29-22.14)], and ages 60+ [aOR=5.04 (95% CI 1.65-15.39), P =0.0482]. In stratified logistic regression analyses among Afro-Caribbean New Yorkers, odds were 18% greater per cm waist circumference [aOR=1.18 (95% CI 1.03-1.35), P =0.0194]. For Afro-Caribbeans, low physical activity was associated with seven times greater odds of type 2 diabetes [aOR=7.03 (95% CI 1.19-41.53), P =0.0314]. Compared to African Americans, Afro-Caribbeans with type 2 diabetes are more likely to have lower waist circumference and be overweight rather than obese despite reporting less physical activity. Further examination of the relationship between BMI, waist circumference and visceral vs. subcutaneous adipose tissue may elucidate important intraethnic differences in diabetes risk. To enhance detection of diabetes among Afro-Caribbeans and African Americans in New York City, screening criteria should consider unique diabetes phenotypes.
Abstract 16538: Circulating Ketone Levels are Associated With Myocardial Infarct Size and Left Ventricular Function in Patients Presenting With St-Elevation Myocardial Infarction
Authors: Marie Sophie L de Koning, B. D Westenbrink, Solmaz Assa, Dirk J van Veldhuisen, Robin P Dullaart, Erik Lipsic, Pim Van Der Harst
Journal: Circulation (2020)

Background: Circulating ketone bodies (KB) are increased in patients with heart failure, corresponding with increased utilization of KB as a cardiac fuel. Whether circulating KB are increased in patients presenting with ST-elevation myocardial infarction (STEMI) and whether this is associated with infarct size is unknown. Methods: KB were measured in 379 non-diabetic participants of the Glycometabolic Intervention as Adjunct to Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction (GIPS) III trial (Clinicaltrial.gov Identifier: NCT01217307). Non-fasting plasma concentrations of the KB beta-hydroxybutyrate, acetoacetate, acetone were measured at presentation, 24 hours and 4 months after STEMI presentation using nuclear magnetic resonance spectroscopy. Associations of circulating KB with myocardial infarct size and left ventricular ejection fraction (both detected with MRI at 4 months after STEMI) were determined using multivariable linear regression analyses. Results: Circulating KB were higher at baseline (total KB 520 [315-997](median [IQR], μmol/L), compared to 206 [174-246] at 24 hours and 166 [143-201] at 4 months ( P &lt;0.001 for all)). KB at 24 hours were positively associated with enzymatic infarct size, HbA1C and beta-blocker use. KB at 24 hours were independently associated with MRI outcomes at 4 months. Higher KB was associated with larger myocardial infarct size (total KB: standardized β=0.17, 95%-confidence interval (CI) (0.04-0.31), P =0.012) and lower ejection fraction (standardized β=-0.15, 95%-CI (-0.29- -0.009), P =0.037). Conclusion: Circulating KB are increased in patients with STEMI and are independently associated with myocardial infarct size and left ventricular function after 4 months of follow-up. The increase in circulating KB may reflect maladaptive changes of myocardial metabolism during the acute phase.
A Rare Case of Evolocumab Induced Atrial Fibrillation
Authors: Ramy Abdelmaseih
Journal: Clinical Cardiology and Cardiovascular Interventions (2021)

Evolocumab, a proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i) is a novel low-density lipoprotein (LDL) lowering agent that has been recently approved by the FDA to reduce the risk of myocardial infarction, stroke, and coronary revascularization in individuals with established atherosclerotic cardiovascular disease, alone or in combination with other lipid-lowering agents, and for treatment of patients with primary hyperlipidemia including familial hypercholesterolemia